Imatinib, a tyrosine kinase inhibitor (TKI), was known to inhibit c-kit as well as BCR-ABL fusion protein, the target of chronic myeloid leukemia (CML). Here, KIT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.